NewsBenzingaargenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026 argenx SE To Present New Data From Phase 3 Study Evaluating VYVGART Hytrulo In Patients With Autoimmune Myositis, Focused On IMNM And DM, At ACR Convergence 2026 Benzinga 2026.10.19 12:07 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Crown Holdings, Raises Price Target to $139 Citigroup Maintains Buy on Capital One Financial, Raises Price Target to $285 10 Billion Reasons Meta’s Q3 EPS Could Shock You, and Not How You Think Citigroup Maintains Neutral on 3M, Raises Price Target to $188 How a SpaceX and Tesla Merger Would Reshape Musk’s AI Empire Citigroup Maintains Buy on SpaceX, Raises Price Target to $240
